PAS
WHWK

Point72 Asia (Singapore)’s Whitehawk Therapeutics WHWK Stock Holding History

Point72 Asia (Singapore)’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,609
Closed -$36.6K – 1266
2024
Q4 		$36.6K Sell
11,609
-512
-4% -$1.16K 0.01% 559
2024
Q3 		$25K Sell
12,121
-13,055
-52% -$21.1K ﹤0.01% 793
2024
Q2 		$36.8K Buy
+25,176
New +$46.7K 0.01% 732

Other funds holding WHWK

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Point72 Asia (Singapore)'s WHWK Position: Q1 2025 in Review

Point72 Asia (Singapore) sold out of Whitehawk Therapeutics (WHWK) in Q1 2025, closing a stake of 11,609 shares — an estimated $36.6K sold.

Point72 Asia (Singapore) first reported a position in WHWK in Q2 2024 and held it in 3 quarters. The position peaked at $36.8K in Q2 2024. 50 funds tracked by Wall St. Rank hold WHWK as of Q1 2025.

  • Point72 Asia (Singapore) reported no remaining Whitehawk Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 11,609 Whitehawk Therapeutics shares in Q1 2025, an estimated $36.6K.
  • Point72 Asia (Singapore) first reported a position in Whitehawk Therapeutics in Q2 2024 and held it in 3 quarters.
  • Point72 Asia (Singapore)'s Whitehawk Therapeutics position peaked at $36.8K in Q2 2024.
  • 50 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q1 2025, filed 15 May 2025.